Clinical trial · Observational
A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland
A Population-based Prospective Study to Evaluate Clinical Behaviour, Resectability and Survival in 1st Line Metastatic Colorectal Cancer (CRC) Patients in Finland
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* A population-based prospective study to evaluate clinical behaviour, resectability and survival in 1st line metastatic colorectal cancer (CRC) patients in Finland * Primary objective: To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection * Secondary objectives: To assess treatments for mCRC; To assess efficacy of chemotherapy and targeted drugs with overall response rates (ORR), failure free survival (FFS), progression free survival (PFS), and overall survival (OS); To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria; To evaluate whole blood, plasma, serum and tumour block biomarkers and DNA polymorphisms that may predict drug effects, resectability and clinical behaviour of the tumour
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biomarker sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- mCRC treatments
- description
- All used treatments for metastatic colorectal cancer
- interventionNames
- Other: Biomarker sampling
Primary outcomes (1)
- measure
- Resectability
- timeFrame
- 5 years
- description
- To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection
Secondary outcomes (3)
- measure
- Efficacy
- timeFrame
- 5 years
- description
- Response rates
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histologically confirmed CRC, who are scheduled to start or are getting first line chemotherapy for metastatic disease 2. Age \> 18 3. Metastatic disease (including locally advanced disease not amenable with surgery and/or (chemo)radiotherapy) 4. Signed written informed consent according to ICH/GCP and the local regulations (approved by the Independent Ethics Committee \[IEC\]) will be obtained prior to study 5. No informed consent will be obtained from patients participating in the data collection study obtaining data from hospital charts. No blood sampling, nor contacting of patients will be performed.
References
Publications (2)
- DERIVEDUutela A, Osterlund E, Halonen P, Kallio R, Algars A, Salminen T, Lamminmaki A, Soveri LM, Ristamaki R, Lehtomaki K, Stedt H, Heerva E, Muhonen T, Kononen J, Nordin A, Ovissi A, Kytola S, Keinanen M, Sundstrom J, Nieminen L, Makinen MJ, Kuopio T, Ristimaki A, Isoniemi H, Osterlund P. Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study. Br J Cancer. 2022 Sep;127(4):686-694. doi: 10.1038/s41416-022-01858-8. Epub 2022 May 24. PMID 35610367
- DERIVEDUutela A, Ovissi A, Hakkarainen A, Ristimaki A, Lundbom N, Kallio R, Soveri LM, Salminen T, Algars A, Halonen P, Ristamaki R, Nordin A, Blanco Sequeiros R, Rinta-Kiikka I, Lantto E, Virtanen J, Paakko E, Liukkonen E, Saunavaara J, Ryymin P, Lammentausta E, Osterlund P, Isoniemi H; RAXO Study Group. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial). ESMO Open. 2021 Aug;6(4):100208. doi: 10.1016/j.esmoop.2021.100208. Epub 2021 Jul 26. PMID 34325107